Phase 1 N=8 Safety and Immunogenicity of Rotavirus Vaccine (RotaTeq(R)) in Infants With Short Bowel Syndrome
Short Bowel Syndrome
Primary: Safety and Tolerability of the Oral RotaTeq® Vaccine — 18; 3 Individual Adverse Events
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=420 Causes of Rotavirus Vaccine Failure in Zambian Children
Diarrhoea
Primary: Proportion of Immunized Infants Exposed to High Breast Milk Anti-rotavirus Immunoglobulin-A Who Fail to Seroconvert — 0.602 Proportion of exposed infants
N/A N=362 Effectiveness of Monovalent Rotavirus Vaccine (RV1)
Rotavirus · Acute Gastroenteritis
Primary: Matched VE Participants in the Minimum Age Model — 31; 70; 6; 31 Participants
Phase 3 N=700 Exploration of the Biologic Basis for Underperformance of Oral Polio and Rotavirus Vaccines in Bangladesh
Rotavirus Diarrhea · Vaccine Virus Shedding · Tropical Enteropathy
Primary: Presence of Fecal Shedding of Polio Vaccine Virus Determined by Culture (Polio Trial) — 99; 109 Participants — p=0.4
Phase 2 N=202 Safety and Immune Response of a Rotavirus Vaccine in HIV-infected and Uninfected Children Born to HIV-infected Mothers
HIV Infection · Rotavirus Infection
Primary: Percentage of Participants Developing New Grade >=3 Adverse Events — 1.6; 4.7; 13.5; 12.8 Percentage of participants — p=0.62
Phase 4 N=66 An Alternate Dosing Schedule for Pentavalent Rotavirus Vaccine (RotaTeq)
Diarrhea · Gastroenteritis
Primary: G1 Serum-neutralizing Antibody — 188; 184.5 titers
Phase 4 N=101 Potential Mechanisms for Intussusception After Rotavirus Vaccine-Pilot Study
Intussusception · Rotavirus Infections
Primary: The Effects of RV1 and RV5 With or Without Other Routine Immunizations on Gastrointestinal Anatomy — 2; 1; 0; 1 Participants — p=0.2
Phase 2 N=204 Phase I/II Descending Age Study of P2VP8 Subunit Parenteral Rotavirus Vaccine in Healthy Toddlers and Infants
Evaluation of a Rotavirus Vaccine
Primary: Number of Participants With Vaccine Induced Reactions — 3; 8; 4; 6 Participants
Phase 2 N=618 Safety and Immunogenicity Study of Trivalent P2-VP8 Subunit Rotavirus Vaccine in Adults, Toddlers and Infants
Healthy
Primary: Number of Participants Experiencing Adverse Events (AE) Within 28 Days of Any Vaccination — 0; 0; 0; 0 Participants
Phase 4 N=93 Yield of Diagnostic Tests and Effects of Crofelemer for Chronic Idiopathic Diarrhea In Non-HIV Patients
Chronic Diarrhea of Unknown Origin
Primary: Number of Participants With a 50 Percent Decrease in Mean Stool Count — 17 Participants
Phase 4 N=220 The Effects of Increased Inoculum on Oral Rotavirus Vaccine Take and Immunogenicity
Rotavirus Infection · Vaccine Response Impaired · Vaccine Virus Shedding
Primary: Number (or Percentage) of Infants in Each Study Arm Who Test Positive for Fecal Rotavirus Vaccine-strain Virus Shedding Post-vaccination — 63; 55 Participants
Phase 4 N=480 Coadministration of Measles-rubella and Rotavirus Vaccines
Measles Antibody Seroconversion · Rubella Antibody Seroconversion · Rotavirus Geometric Mean Titer (GMT)
Primary: Percentage/Number of Subjects With Seroprotection for Measles Virus Serum Neutralization Antibodies — 171; 173; 56; 60 Participants
Phase 4 N=620 Zinc and/or Probiotic Supplementation of Rotavirus and Oral Polio Virus Vaccines
Immunity to Oral Rotavirus Vaccine · Immunity to Oral Polio Vaccine · Shedding of Oral Rotavirus Vaccine
Primary: Number/Percentage of Subjects With Immune Response to Rotavirus Vaccine — 54; 40; 42; 37 Participants
Phase 3 N=8,237 Vaccine Efficacy Against Rotavirus Diarrhea; Vaccine Given With Routine Childhood Vaccinations in Healthy African Infants
Infections, Rotavirus
Primary: Number of Subjects With Severe Rotavirus Gastroenteritis (RV GE) Caused by the Circulating Wild-type Rotavirus Strain — 30; 26; 56; 70 subjects
N/A N=71 Oral Zinc for the Treatment of Acute Diarrhea in US Children
Diarrhea · Gastroenteritis
Primary: Duration of Diarrhea in Acute Diarrheal Illnesses in a Developed Nation While Taking Zinc or Placebo. — 73; 72; 48; 76.8 Hours — p=0.88